March 2015
Volume 56, Issue 3
Free
Erratum  |   March 2015
Erratum
Investigative Ophthalmology & Visual Science March 2015, Vol.56, 1473-1474. doi:https://doi.org/10.1167/iovs.13-13054a
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum. Invest. Ophthalmol. Vis. Sci. 2015;56(3):1473-1474. https://doi.org/10.1167/iovs.13-13054a.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Erratum in: “Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes” by Seong Joon Ahn, Jeeyun Ahn, Sunyoung Park, Hyuncheol Kim, Duck Jin Hwang, Ji Hyun Park, Ji Yeon Park, Jae Yong Chung, Kyu Hyung Park, and Se Joon Woo (Invest Ophthalmol Vis Sci. 2014;55:567–573) doi:10.1167/iovs.13-13054 
The unit used for ranibizumab concentrations in the rabbit retina should be ng instead of μg. The statistical results and conclusions are not affected by this error. 
In Table 1, the unit used for total amount of ranibizumab in retina should be ng, and the unit used for ranibizumab concentration in retina should be ng/g. The corrected Table appears below. 
Table 1
 
Amount of Ranibizumab in the Three Compartments (Aqueous Humor, Vitreous, and Retina) of 18 Vitrectomized and 18 Nonvitrectomized Rabbit Eyes at 1 Hour, or at 1, 2, 5, 14, or 30 Days After Intravitreal Injection
Table 1
 
Amount of Ranibizumab in the Three Compartments (Aqueous Humor, Vitreous, and Retina) of 18 Vitrectomized and 18 Nonvitrectomized Rabbit Eyes at 1 Hour, or at 1, 2, 5, 14, or 30 Days After Intravitreal Injection
Time, h Vitrectomized Eyes Nonvitrectomized Eyes
Aqueous Humor Vitreous Retina Aqueous Humor Vitreous Retina
Total, μg Conc, μg/mL Total, μg Conc, μg/mL Total, ng Conc, ng/g Total, μg Conc, μg/mL Total, μg Conc, μg/mL Total, ng Conc, ng/g
1 h 4.34 ± 0.41 21.7 ± 2.07 177.02 ± 10.62 118.01 ± 7.08 23.63 ± 6.61 984.53 ± 275.40 4.08 ± 0.47 20.38 ± 2.37 137.42 ± 14.64 91.61 ± 9.76 22.85 ± 0.08 952.25 ± 3.31
1 d 2.88 ± 0.27 14.4 ± 1.36 136.70 ± 8.55 91.13 ± 5.70 17.95 ± 3.21 748.08 ± 133.95 2.81 ± 0.10 14.04 ± 0.49 100.01 ± 1.74 66.67 ± 1.16 14.00 ± 1.28 583.54 ± 53.28
2 d 2.45 ± 0.16 12.3 ± 0.78 90.86 ± 6.60 60.57 ± 4.40 10.69 ± 3.42 445.58 ± 142.35 2.35 ± 0.10 11.75 ± 0.48 80.75 ± 4.35 53.83 ± 2.90 8.48 ± 1.70 353.19 ± 70.74
5 d 0.69 ± 0.00 3.43 ± 0.01 26.58 ± 3.00 17.72 ± 2.00 7.93 ± 3.49 330.49 ± 145.49 0.61 ± 0.03 3.03 ± 0.16 22.92 ± 3.51 15.28 ± 2.34 5.94 ± 0.62 247.64 ± 25.95
14 d 0.24 ± 0.09 1.20 ± 0.43 3.29 ± 0.05 2.19 ± 0.03 1.46 ± 0.55 60.80 ± 23.02 0.43 ± 0.09 2.13 ± 0.45 3.80 ± 0.56 2.53 ± 0.37 2.05 ± 0.20 85.25 ± 8.21
30 d 0.02 ± 0.07 0.12 ± 0.33 0.96 ± 0.29 0.64 ± 0.19 0.72 ± 0.21 29.89 ± 8.57 0.15 ± 0.06 0.75 ± 0.28 2.22 ± 0.26 1.48 ± 0.17 0.67 ± 0.27 28.07 ± 11.06
In the Results section, the fourth and fifth sentences in the second paragraph should read: “At that point, 0.25 mg of intravitreally injected ranibizumab was distributed to the aqueous humor at 4.34 μg (1.7%), 177.02 μg (70.8%) to the vitreous, and 23.63 ng (0.01%) to the retina in vitrectomized eyes. The corresponding amounts of ranibizumab in the nonvitrectomized eyes at the same time point were 4.08 μg (1.6%), 137.42 μg (55.0%), and 22.85 ng (0.01%), respectively.” 
In the Results section, the third and fourth sentences in the last paragraph should read: “The concentration peaked at 1 hour after intravitreal ranibizumab injection (984.53 and 952.25 ng/g in the retina in the vitrectomized and nonvitrectomized eyes, respectively), and subsequent measurements were comparable between the vitrectomized and nonvitrectomized eyes. At 30 days after injection, the ranibizumab concentrations in vitrectomized and nonvitrectomized eyes were 29.89 and 28.07 ng/g, respectively.” 
In Figure 3, the y-axis title should be “Ranibizumab concentration in the retina (ng/g).” In the legend, “micrograms of ranibizumab/g of the retina” should be “nanograms of ranibizumab/g of the retina.” The corrected figure appears below. 
Figure 3
 
Ranibizumab concentrations in the retina (nanograms of ranibizumab/g of the retina) over time in vitrectomized and nonvitrectomized rabbit eyes following intravitreal injection (0.25 mg) are shown.
Figure 3
 
Ranibizumab concentrations in the retina (nanograms of ranibizumab/g of the retina) over time in vitrectomized and nonvitrectomized rabbit eyes following intravitreal injection (0.25 mg) are shown.
Figure 3
 
Ranibizumab concentrations in the retina (nanograms of ranibizumab/g of the retina) over time in vitrectomized and nonvitrectomized rabbit eyes following intravitreal injection (0.25 mg) are shown.
Figure 3
 
Ranibizumab concentrations in the retina (nanograms of ranibizumab/g of the retina) over time in vitrectomized and nonvitrectomized rabbit eyes following intravitreal injection (0.25 mg) are shown.
Table 1
 
Amount of Ranibizumab in the Three Compartments (Aqueous Humor, Vitreous, and Retina) of 18 Vitrectomized and 18 Nonvitrectomized Rabbit Eyes at 1 Hour, or at 1, 2, 5, 14, or 30 Days After Intravitreal Injection
Table 1
 
Amount of Ranibizumab in the Three Compartments (Aqueous Humor, Vitreous, and Retina) of 18 Vitrectomized and 18 Nonvitrectomized Rabbit Eyes at 1 Hour, or at 1, 2, 5, 14, or 30 Days After Intravitreal Injection
Time, h Vitrectomized Eyes Nonvitrectomized Eyes
Aqueous Humor Vitreous Retina Aqueous Humor Vitreous Retina
Total, μg Conc, μg/mL Total, μg Conc, μg/mL Total, ng Conc, ng/g Total, μg Conc, μg/mL Total, μg Conc, μg/mL Total, ng Conc, ng/g
1 h 4.34 ± 0.41 21.7 ± 2.07 177.02 ± 10.62 118.01 ± 7.08 23.63 ± 6.61 984.53 ± 275.40 4.08 ± 0.47 20.38 ± 2.37 137.42 ± 14.64 91.61 ± 9.76 22.85 ± 0.08 952.25 ± 3.31
1 d 2.88 ± 0.27 14.4 ± 1.36 136.70 ± 8.55 91.13 ± 5.70 17.95 ± 3.21 748.08 ± 133.95 2.81 ± 0.10 14.04 ± 0.49 100.01 ± 1.74 66.67 ± 1.16 14.00 ± 1.28 583.54 ± 53.28
2 d 2.45 ± 0.16 12.3 ± 0.78 90.86 ± 6.60 60.57 ± 4.40 10.69 ± 3.42 445.58 ± 142.35 2.35 ± 0.10 11.75 ± 0.48 80.75 ± 4.35 53.83 ± 2.90 8.48 ± 1.70 353.19 ± 70.74
5 d 0.69 ± 0.00 3.43 ± 0.01 26.58 ± 3.00 17.72 ± 2.00 7.93 ± 3.49 330.49 ± 145.49 0.61 ± 0.03 3.03 ± 0.16 22.92 ± 3.51 15.28 ± 2.34 5.94 ± 0.62 247.64 ± 25.95
14 d 0.24 ± 0.09 1.20 ± 0.43 3.29 ± 0.05 2.19 ± 0.03 1.46 ± 0.55 60.80 ± 23.02 0.43 ± 0.09 2.13 ± 0.45 3.80 ± 0.56 2.53 ± 0.37 2.05 ± 0.20 85.25 ± 8.21
30 d 0.02 ± 0.07 0.12 ± 0.33 0.96 ± 0.29 0.64 ± 0.19 0.72 ± 0.21 29.89 ± 8.57 0.15 ± 0.06 0.75 ± 0.28 2.22 ± 0.26 1.48 ± 0.17 0.67 ± 0.27 28.07 ± 11.06
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×